코로나19와 연구윤리
COVID-19 and Research Ethics
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
이 글에서는 코로나19 범유행과 같은 재난 상황에서의 연구윤리의 특성, 이때 고려해야 할 연구윤리 가치와 원칙, 재난 상황에 적합한 심의 체계와 방법론, 주요 윤리적 쟁점 및 국내 코로나19 관련 연구윤리 현황에 대해 살펴보았다. 재난 상황에서 고려해야 할 연구윤리 원칙으로는 과학적 타당성, 사회적 가치, 위험 대비 이익 비율, 시간에 민감한 심의, 설명 동의 등이 있다. 앞으로 계속 발생할 것으로 예상되는 범유행병에 대비하여 재난 상황에서의 연구윤리 지침을 개발할 필요가 있으며, 이를 기반으로 철저하되 시간에 민감한 윤리성 심의를 진행해야 한다. 이때 연구대상자에 대한 잠재적 이익과 위험, 과학적 타당성, 사회적 가치 등을 조화시켜야 하며, 연구대상자의 참여는 과학적 근거에 기반해야 한다. 아울러 재난 상황에 적합한 국가 차원의 연구와 연구윤리 거버넌스에 대한 총체적인 검토와 계획이 필요하다.
Abstract
This article examines disaster-related research ethics in terms of its values, principles, systems of review, and methodologies. The article also reviews some of the major ethical issues in, and current status of, research ethics related to COVID-19 in Korea. Principles to be considered in disaster-related research include scientific validity, social value, risk-to-benefit ratio, time-sensitive reviews, and informed consent. It is necessary to develop guidelines for disaster-related research ethics that facilitate complete, yet time-sensitive ethical reviews. The potential benefits, scientific validity, and social value of research plans should be harmonized, and the participation of research subjects should be based on scientific evidence. A comprehensive review and plan for national-level research and research ethics governance appropriate to disasters is needed in Korea.
참고문헌 (43)
- 전주연, "The Impact of COVID-19 on the Conduct of Clinical Trials for Medical Products in Korea", Journal of Korean Medical Science, 35(36), pp.1~13 (2020), 대한의학회[DOI]
- 신희영, "코로나19 IRB 심의", Journal of KAIRB, 2(2), pp.33~37 (2020)
- Callaway, E., "Will the pandemic permanently alter scientific publishing?", Nature, 582(7811), pp.167~168 (2020)
- Besançon L, "Open science saves lives: lessons from the COVID-19 pandemic", BioRxiv, ~ (2020)
- Muller MP, "Clinical trials and novel pathogens : lessons learned from SARS", Emerg Infect Dis, 10(3), pp.389~ (2004)
- Research ethics in international epidemic response: WHO technical consultation, Geneva, Switzerland, 10-11 Jun 2009: meeting report, "World Health Organization", World Health Organization, ~ (2009)
- Chor JSY, "Willingness of Hong Kong healthcare workers to accept pre-pandemic influenza vaccination at different WHO alert levels: two questionnaire surveys", BMJ, 339, pp.b3391~ (2009)
- 최은경, "COVID-19 대유행 속 백신 개발을 둘러싼 윤리적 쟁점", 생명, 윤리와 정책, 4(2), pp.1~18 (2020), (재) 국가생명윤리정책원[DOI]
- "TCPS 2 (2018) – Chapter 6: governance of research ethics review d. research ethics review during publicly declared emergencies" (2018)[URL]
- Schopper D, "Research ethics review in humanitarian contexts : the experience of the independent ethics review board of Médecins Sans Frontières", PLoS Med, 6(7), pp.e1000115~ (2009)
- "MSF research ethics framework–guidance document" (2013)[URL]
- Tansey CM, "A framework for research ethics review during public emergencies", CMAJ, 182(14), pp.1533~1537 (2010)
- Sumathipala A, "Ethical issues in post-disaster clinical interventions and research: a developing world perspective. Key findings from a drafting and consensus generation meeting of the Working Group on Disaster Research and Ethics (WGDRE) 2007", Asian Bioethics Review, 2(2), pp.124~142 (2010)
- Emanuel EJ, "What makes clinical research in developing countries ethical? the benchmarks of ethical research", J Infect Dis, 189(5), pp.930~937 (2004)
- "An ethical framework for the development and review of health research proposals involving humanitarian contexts" (2014)[URL]
- World Health Organization, "Guidance for managing ethical issues in infectious disease outbreaks", World Health Organization, ~ (2016)
- Alexander PE, "COVID-19 coronavirus research has overall low methodological quality thus far : case in point for chloroquine", hydroxychloroquine, 2020, pp.123, 120~126
- Council for International Organizations of Medical Sciences, "International ethical guidelines for health-related research involving humans", Council for International Organizations of Medical Sciences, ~ (2016)
- Lambkin-Williams R, "A COVID-19 human viral challenge model. learning from experience", Influenza Other Respir Viruses, 14(6), pp.747~756 (2020)
- Hunt M, "The challenge of timely, responsive and rigorous ethics review of disaster research: views of research ethics committee members", PLoS One, 11(6), pp.e0157142~ (2016)
- Schopper D, "Disaster bioethics: normative issues when nothing is normal", pp.75~190 (2014), Springer
- Presidential Commission for the Study of Bioethical Issues, "Ethics and ebola: public health planning and response" (2015), Presidential Commission for the Study of Bioethical Issues
- Nuffield Council on Bioethics, "Research in global health emergencies : ethical issues" (2020), Nuffield Council on Bioethics
- Edwards SJL, "Ethics of clinical science in a public health emergency : drug discovery at the bedside", Am J Bioeth, 13(9), pp.3~14 (2013)
- Saxena A, "Ethics preparedness : facilitating ethics review during outbreaks-recommendations from an expert panel", BMC Med Ethics, 20(1), pp.29~ (2019)
- World Health Organization, "Guidance for research ethics committees for rapid review of research during public health emergencies" (2020), World Health Organization
- Macklin R, "Conducting research in disease outbreaks", PLoS Negl Trop Dis, 3(4), pp.e335~ (2009)
- Pan American Health Organization, "Guidance and strategies to streamline ethics review and oversight of COVID-19 related research", Pan American Health Organization, ~ (2020)
- Eckenwiler L, "Real-time responsiveness for ethics oversight during disaster research", Bioethics, 29(9), pp.653~661 (2015)
- HIS, "Ethical issues related to study design for trials on therapeutics for Ebola Virus Disease: WHO Ethics Working Group meeting 20-21 October, summary of discussion. No. WHO", pp.14.2, KER
- "Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine" (2020)[URL]
- Aquino YSJ, "Hydroxychloroquine and COVID-19 : critiquing the impact of disease public profile on policy and clinical decisionmaking", J Med Ethics, 46(9), pp.574~578 (2020)
- "Emergency use of unproven interventions outside of research. ethics guidance for the COVID-19 pandemic" (2020)[URL]
- Webb J, "Ethically allocating COVID-19 drugs via pre-approval access and emergency use authorization", Am J Bioeth, 20(9), pp.4~17 (2020)
- 보건복지부, "공용IRB, 코로나19 연구에 대한 IRB 심의면제 확인 개시. 2020년 4월 29일", ~ (2020)
- 식품의약품안전처, "COVID-19 관련 임상시험 고려사항. 2020년 3월 20일", ~ (2020)
- 식품의약품안전처, "COVID-19 관련 임상시험 고려사항. 2021년 1월 12일", ~ (2021)
- 식품의약품안전처, "의약품 임상시험심사위원회 긴급심사 권고사항. 2020년 11월 30일", ~ (2020)
- "에볼라치료제 ‘렘데시비르’ 국내서도 코로나19 환자에 쓴다" (2020)[URL]
- "식약처, 코로나19 치료제 렘데시비르 품목 허가. 2020.7.24" (2020), 조선비즈[URL]
- "More than 1,700 COVID-19 clinical trials registered worldwide" (2020)[URL]
- 코로나19 치료제·백신 개발 범정부지원위원회기업 애로사항 해소 지원센터, "코로나19 치료제·백신 등 개발 주요 질의·답변. 2021년 3월", ~ (2021)
- Sheehy A, "Implementing a national approach to research ethics review during a pandemic–the Irish experience", HRB Open Res, 3, pp.63~ (2020)
